Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions

Core Insights - Daxor Corporation is participating as an exhibitor at the American College of Cardiology Annual Scientific Session, showcasing its innovative Blood Volume Analyzer [1][2] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, addressing the critical issue of accurately measuring blood volume to improve patient care and reduce healthcare costs [5] - The company has developed a rapid, portable Blood Volume Analyzer (BVA) that is FDA-cleared and provides over 95% accuracy in quantifying total blood, plasma, and red cell volume [2][5] Product Benefits - The BVA system replaces subjective clinical guesswork with objective data, which is essential for optimizing fluid management and discharge timing in patients [3] - Peer-reviewed studies indicate that BVA-guided care can lead to a 56% reduction in 30-day readmissions and an 82% reduction in 30-day mortality, demonstrating significant value for healthcare providers [3] Market Context - The BVA addresses the $3.5 billion annual Medicare burden associated with heart failure readmissions in the United States, highlighting its potential impact on healthcare costs [2] - Daxor's technology is positioned for scalability across both inpatient and outpatient care environments, enhancing its market reach [3]